Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in it ...

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2021 Results Earnings Conference Call March 28, 2022 8:00 AM ET Company Participants Michael Wood - Investor Relations, LifeSci Advisors Chaim Lebovits - Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Ralph Kern - President and Chief Medical Officer Stacy Lindborg - Executive Vice President and Chief Development Officer Conference Call Participants David Bautz - Zachs SCR Michelle Lorenz - Voices for ALS Operator Good day, ladies and ...

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2021 Earnings Conference Call November 15, 2021 8:00 AM ET Company Participants Michael Rice - Investor Relations, LifeSci Advisors Chaim Lebovits - President & Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Stacy Lindborg - Executive Vice President & Chief Development Office Ralph Kern - President & Chief Medical Officer David Setboun - Executive Vice President & Chief Operating Officer Conference Call Participants Michael Rabinowit ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in its ...

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2021 Earnings Conference Call April 26, 2021 8:00 AM ET Company Participants Michael Wood - IR, LifeSci Advisors Chaim Lebovits - President and CEO Dr. Stacy Lindborg - EVP and Head, Global Clinical Research Dr. Ralph Kern - President and Chief Medical Officer Dr. Preetam Shah - EVP and CFO Dr. David Setboun - EVP and COO Conference Call Participants David Bautz - Zacks Small Cap Research Operator Greetings. Welcome to BrainStorm Cell Therapeutics’ First Qu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to _____________ Commission File Number 001-36641 BRAINSTORM CELL THERAPEUTICS INC. (Exact name of registrant as specified in it ...

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2020 Earnings Conference Call February 4, 2021 8:00 AM ET Company Participants Michael Wood - LifeSci Advisors, LLC Chaim Lebovits - Chief Executive Officer Ralph Kern - President and Chief Medical Officer Stacy Lindborg - Executive Vice President and Head of Global Clinical Research Preetam Shah - Executive Vice President and Chief Financial Officer Conference Call Participants David Bautz - Zacks Investment Research Operator Greetings and welcome to the B ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 ¨ TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |--------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------| | FOR THE TRANS ...

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2020 Earnings Conference Call October 15, 2020 8:00 AM ET Company Participants Michael Wood - LifeSci Advisors, LLC Chaim Lebovits - President and Chief Executive Officer Ralph Kern - President and Chief Medical Officer Stacy Lindborg - Executive Vice President and Head of Global Clinical Research Preetam Shah - Executive Vice President and Chief Financial Officer David Setboun - Executive Vice President and Chief Operating Officer Anthony Waclawski - Execu ...